New anti-HIV drug begins phase II clinical trial
New anti-HIV drug begins phase II clinical trial
Durham, NC-based Trimeris recently announced that it has begun a Phase II clinical trial for T-20, a new class of anti-viral fusion-inhibiting drugs that block HIV infection. The study will determine the optimal dosing for T-20 as well as the feasibility of its administration via an infusion device developed by MiniMed, a product currently approved for insulin infusion by diabetics.
T-20 is designed to block both virus-to-cell and cell-to-cell membrane fusion, thus preventing a critical early step in the spread of viral infection. Phase I/II clinical trials against HIV infection were completed last year, with the drug demonstrating potent anti-HIV activity and no drug-related adverse effects in the 16 patients tested.
The next trial will enroll 32 HIV-infected patients who have failed existing triple combination therapy.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.